NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

Saturday, May 27

7:30am – 5:00pm 

Earn AMA PRA Category 1 Credits,™ Continuing Nursing Education (ANCC), and MOC accreditation

On-Line Registration is Closed

Location

Park Hyatt Toronto
4 Avenue Road, Toronto, ON. M5R 2E8

Providers

Jointly Provided by Sunnybrook Health Sciences Centre and the North American Neuroendocrine Tumor Society

 

Course Directors

Julie Hallet, MD, MSC, FRCSC, Sunnybrook Health Sciences Centre

Simron Singh, MD, MPH, FRCPC, Odette Cancer Center at Sunnybrook Health Sciences Cente

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment, and management of NETs are time-consuming, complex, and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
• Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
• Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
• Recognize the clinical features associated with carcinoid syndrome
• Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
• Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

Program

*Program is tentative and subject to change*

• • Julie Hallet, MD, MSc, FRCSC, Associate Scientist, Sunnybrook Health Sciences Centre, and Simron Singh, MD, MPH, FRCPC, Medical Oncologist and Affiliate Scientist, Odette Cancer Centre, Sunnybrook Health Sciences Centre

• • NETs Epidemiology
    Simron Singh, MD, MPH, FRCPC, Medical Oncologist and Affiliate Scientist, Odette Cancer Centre, Sunnybrook Health Sciences Centre
  • NETs Functional Imaging
    Nadine Mallak, MD, Associate Professor of Diagnostic Radiology, Oregon Health, and Science University
  • I found a NET, now what? Management of incidental NETs
    Calvin Law, MD, FRCSC, Professor, Sunnybrook Health Sciences Centre
  • Moderator, Sara Temple, Chief of Surgery, Southlake Regional Health Centre

• • Work-up & Endocrine Management of PNETs
    Angela Assal, MD, MHSc, FRCPC, Staff Physician, Assistant Professor, Sunnybrook Health Sciences Centre
  • Surgical Management of functional PNETs
    Callisia N. Clarke, MD, MS, FACS, FSSO, Associate Professor, Medical College of Wisconsin
  • Pheochromocytma and Paraganglioma Guidelines
    Jaydira Del Rivero, MD, Associate Research Physician, National Cancer Institute, National Institutes of Health
  • Moderator, Sean Bennett, MD, Assistant Professor, Attending Staff, Kingston Health Sciences Centre

• • Systemic Therapy for Lung NETs
    Daniel Rayson, MD, FRCPC, FACP, Professor, Dalhousie University & Nova Scotia Health
  • Surgical Management of Lung NETs
    Mathieu Rousseau, MD, CM, CCFP, PhD, McGill University
  • Moderator, Shivani Dadwal, MD, FRCPC, Medical Oncologist, Kingston Health Sciences Centre

• • Advances in Systemic Therapy
    Jennifer Chan, MD, MPH, Clinical Director, Gastrointestinal Cancer Center, Director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School
  • Advances in PRRT: Repeat and Combination Therapy
    Aman Chauhan, MD, Leader of the Neuroendocrine Tumor Program, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine
  • Moderator, David Laidley, MD, Nuclear Medicine Residency Program Director, Assistant Professor, St. Joseph's Health Care

• • Systemic Therapy for G3 NENs
    Aman Chauhan, MD, Leader of the Neuroendocrine Tumor Program, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine
  • Role of Surgery for G3 NENs
    Alexandra Gangi, MD, Director, Gastrointestinal Tumor Program, Surgical Oncology, Department of Surgery, Cedars-Sinai
  • Moderator, Suneil Khanna, MD, FRCPC, Sunnybrook Health Sciences Centre

• • Surgery and Liver-Directed Therapy
    Julie Hallet, MD, MSc, FRCSC, Associate Scientist, Sunnybrook Health Sciences Centre
  • Ablative Therapy/ SABR
    Sten Myrehaug, MD, FRCPC, Assistant Professor, University of Toronto
  • Moderator, Shaqil Kassam, MD, MSc, FRCPC, Medical Oncologist, Stronach Regional Cancer Centre

• • Screening, Diagnosis, and Management
    Shaheeda Ahmed, MDCM, FRCPC, FACC, Assistant Professor, Sunnybrook Health Sciences Centre
  • Peri-procedural considerations
    Stephanie Ladowski, MD, Anesthesiologist, Sunnybrook Health Sciences Centre
  • Moderator, Yasmin Essaji, MD, McMaster University Medical Centre

• • Clinical trials at NIH – Access for Canadians
    Jaydira Del Rivero, MD,  Associate Research Physician, National Cancer Institute, National Institutes of Health
  • Clinical trials in Canada
    Simron Singh, MD, MPH, FRCPC, Medical Oncologist and Affiliate Scientist, Odette Cancer Centre, Sunnybrook Health Sciences Centre
  • Moderator, William Raskin, MD, Medical Oncologist, William Osler Health Systems

• • Case Presenter: Daryl Gray, BSc, MD, FRCSC, FACS, Associate Professor, London Health Sciences Centre
  • Angela Assal, MD, MHSc, FRCPC, Staff Physician, Assistant Professor, Sunnybrook Health Sciences Centre
  • Callisia N. Clarke, MD, MS, FACS, FSSO, Associate Professor, Medical College of Wisconsin
  • Jennifer Chan, MD, MPH, Clinical Director, Gastrointestinal Cancer Center, Director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School
  • Nadine Mallak, MD, Associate Professor of Diagnostic Radiology, Oregon Health, and Science University

• • Case Presenter: Calvin Law, MD, FRCSC, Professor, Sunnybrook Health Sciences Centre
  • Alexandra Gangi, MD, Director, Gastrointestinal Tumor Program, Surgical Oncology, Department of Surgery, Cedars-Sinai
  • Simron Singh, MD, MPH, FRCPC, Medical Oncologist and Affiliate Scientist, Odette Cancer Centre, Sunnybrook Health Sciences Centre
  • Stephanie Ladowski, MD, Anesthesiologist, Sunnybrook Health Sciences Centre
  • Shaheeda Ahmed, MDCM, FRCPC, FACC, Assistant Professor, Sunnybrook Health Sciences Centre

• • Case Presenter: Negar Ahmadi, MD, Assistant Professor, Surgeon- Teacher, University of Toronto
  • Aman Chauhan, MD, Leader of the Neuroendocrine Tumor Program, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine
  • Elliot Wakeam, MD, Assistant Professor, Surgeon- Investigator, Toronto General Hospital
  • Nadine Mallak, MD, Associate Professor of Diagnostic Radiology, Oregon Health, and Science University

• • Case Presenter: Sean Bennett, MD, Assistant Professor, Attending Staff, Kingston Health Sciences Centre
  • Calvin Law, MD, FRCSC, Professor, Sunnybrook Health Sciences Centre
  • Jennifer Chan, MD, MPH, Clinical Director, Gastrointestinal Cancer Center, Director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School
  • Jaydira Del Rivero, MD,  Associate Research Physician, National Cancer Institute, National Institutes of Health
  • Sten Myrehaug, MD, FRCPC, Assistant Professor, University of Toronto

Accreditation

This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians for ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation enables the participant to earn up to 6.75 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 6.75 hours of continuing nursing education credit.

Registration fee:

NANETS Member

$65 USD - MD, PharmD, Doctoral Level 
$35 USD - Allied Health
Complimentary - Student/Fellow/Resident

Non-Member

$95 USD - MD, PharmD, Doctoral Level 
$50 USD - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before May 5, 2023. On or after May 6, 2023, no refund will be made.

Sunnybrook Health Sciences Centre, the University of Toronto, and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.